Published: Tue, June 06, 2017
Markets | By Noel Gibbs

Which Analysts Are Watching TG Therapeutics, Inc. (TGTX)?


Investors sentiment increased to 2.35 in Q4 2016. Its up 1.68, from 0.67 in 2016Q3.

Shares of TG Therapeutics Inc (NASDAQ:TGTX) declined -6.14% to $13.00. Legal & General Group Plc raised its stake in shares of TG Therapeutics by 4.1% in the first quarter. TG Therapeutics, Inc. (NASDAQ:TGTX), at its latest closing price of $13.85, it has a price-to-book ratio of 9.15, compared to an industry average at 15.32. Royal Natl Bank Of Canada reported 1,429 shares. 223,851 were accumulated by New York State Common Retirement Fund. Cubist Systematic Strategies Lc holds 38,622 shares or 0.01% of its portfolio. The Ra Capital Management Llc holds 1.00M shares with $4.67M value, down from 4.63M last quarter.

Plante Moran Ltd Liability Corp invested in 0% or 52 shares.

Preds tip Pens, even Stanley Cup
They ruled Gaudreau's wraparound attempt slid the puck just over the goal line before Penguins goaltender Matt Murray stopped it. Nashville won both their home match and restored parity in the final series of the playoffs against the Pittsburgh penguins.


At the end of Mar reporting period, 69 institutional holders increased their position in TG Therapeutics, Inc. Henderson Grp Public Limited Com stated it has 844 shares or 0% of all its holdings.

The share price of TG Therapeutics, Inc. Kcg has invested 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). The company's shares were given away at $11.17 per share worth to an income of some $78,190 on account of Charney Laurence N. Columbus Circle owns 776,699 shares.

Since December 30, 2016, it had 0 insider buys, and 3 sales for $206,091 activity. KENNEDY WILLIAM JAMES had sold 8,548 shares worth $87,788.

Gym of one of attackers saw 'nothing of concern'
The other attacker, Rachid Redouane, 30, claimed to be Moroccan-Libyan descent, also lived in the same area of east London . Pakistani-born Khuram Shazad Butt was on the radar of the police and MI5 and had apparently been investigated in 2015.


Shares of the company have shown an EPS growth of 40.90% in the last 5 years.

Looking further out, over the past twelve months, TG Therapeutics, Inc.'s stock was 64.35% and 27.45% over the last quarter and 138.53% for the past six months. (TGTX) has a trading volume of 7.54 Million shares, with an average trading volume of 1640 shares - with shares dropping to a 52 week low of $4.10, and the company's shares hitting a 52 week high of $ 15.05. The 1-year high was reported on Jun, 6 by Barchart.com. We have $12.08 PT which if reached, will make NASDAQ:TGTX worth $71.40 million less. The RSI computes momentum as the ratio of higher closes to lower closes: stocks which have had more or stronger positive changes have a higher RSI than stocks which have had more or stronger negative changes. About 5.71M shares traded or 291.10% up from the average. Ltd. (NASDAQ:RADA) has risen 30.95% since June 6, 2016 and is uptrending. It has outperformed by 43.84% the S&P500.

Among 10 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 100% are positive. Finally, Aegis started coverage on shares of TG Therapeutics in a report on Wednesday, February 22nd. FBR Capital initiated the shares of TGTX in report on Tuesday, December 1 with "Outperform" rating. Raymond James initiated the shares of TGTX in report on Wednesday, September 9 with "Strong Buy" rating. As per Thursday, October 6, the company rating was reinitiated by Brean Capital. A stock rating will generally tell the investor how well a stock's market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The rating was maintained by H.C. Wainwright on Tuesday, March 7 with "Buy". Zacks upgraded the shares of TGTX in report on Wednesday, August 12 to "Hold" rating. Suntrust Robinson initiated it with "Buy" rating and $18 target in Friday, May 27 report. "Recaps Schedule of Clinical Data Presentations at the ..." on June 02, 2017. Announces Successful Outcome from Pre-Planned Interim ..." published on May 23, 2017, Nasdaq.com published: "TG Therapeutics, Inc.

Qatar says Kuwait trying to mediate, solve rift with Gulf Arab nations
Saudi Arabia said the move was necessary to protect the kingdom from what it described as terrorism and extremism. The Sunni-ruled Arab nations are unhappy with Qatar's ties to Shiite-ruled Iran .


TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The firm's market capitalization is $801.53 million. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. The company's current price-earnings ratio amounts above the average P/E ratio of 150.55 times earnings. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Like this: